Insight

Insights,

| Stacey Gilbert, MPH, MBA - Director, Precision Medicine

The MolDX Technical Assessment: How to Move Your Test from “Not Successful” to Medicare Coverage Success

Insights,

| Stacey Gilbert, MPH, MBA - Director, Precision Medicine

CRUSH and Genetic and Molecular Laboratories: A Potential Shift in Medicare Oversight

Insights,

| Stacey Gilbert, MPH, MBA - Director, Precision Medicine

March Is Colorectal Cancer Awareness Month: Why CMS’s Proposed NCD 210.3 Update Could Accelerate Patient‑Centered Screening Access

Insights,

| Marc Samuels, JD, MPH - Chief Executive Officer

MFN shifts from noise to credible threat

Insights,

| Marc Samuels, JD, MPH - Chief Executive Officer

The 2026 Rare Disease Reality

Insights,

| Stacey Gilbert, MPH, MBA - Director, Precision Medicine

A New Era for Cancer Detection Begins with the Sewell MCED Law

Insights,

| Ashis Kumar Das, MD, MPH, PhD - Director

How HEOR and Real-World Evidence Are Reshaping Decisions in 2026

Insights,

| Marc Samuels, JD, MPH - Chief Executive Officer

AI in the Patient Care Paradigm: Examining Regulatory Challenges to Clinical Adoption  

Insights,

| Stacey Gilbert, MPH, MBA - Director, Precision Medicine

FDA Proposes Down-Classification of Oncology Companion Diagnostics: A Q&A on Precision Medicine